SCANCELL (SCNLF) - VACCINES AGAINST CANCER
Post# of 10
Posted On: 03/23/2014 3:27:22 PM
About Scancell:
Scancell is a British company that develops vaccines to treat cancer. The company has two types of vaccines; ImmunoBody and Moditope.
ImmunoBody is a reprogrammable DNA vaccine that can be reconfigured to treat any kind of cancer by making small alterations in the vaccine's DNA code.
Moditope uses special chemicals that Scancell has discovered and patented that cause cancer patients to produce a rare super powerful cancer killing immune cell called a killer CD4 T cell. CD4 T cells usually function as helper cells but Scancell's special chemicals cause these cells to switch their roles from helpers to cancer killing cells, far more powerful than the killer cells that exist in people normally.
Scancell has several ImmunoBody DNA vaccines in development. SCIB1 to treat skin cancer, SCIB2 to treat lung cancer and other ImmunoBody vaccines at an early stage including one to treat prostate cancer. SCIB1 is currently in Phase 2 clinical trials. SCIB2 is now ready to enter human trials.
The first Moditope vaccine Modi-1 is making progress and will be used to treat breast cancer, cervical cancer and womb cancer. But because Moditope is such a special discovery some of the component chemicals used to make Moditope vaccines will be made available by out-licensing to vaccine developers worldwide providing the licensed vaccines don't duplicate Scancell's.
Because Scancell's vaccines teach the immune system to fight cancer they are described as cancer immunotherapies.
Citigroup analyst Andrew Baum has estimated that cancer immunotherapies will have potential sales of $35 billion a year within the next 10 years and could become the biggest drug class in history!
All Scancell's vaccines are non-toxic, targeting cancer but leaving healthy cells untouched.
Scancell's shares trade in London (SCLP.L), Frankfurt (SCP) and New York (SCNLF).
Official Profile
Here is a summary published by Scancell, taken from the conference guide for the 2014 Sachs Annual Life Science CEO forum held in Zurich this month:
Scancell is listed on AIM (part of the London Stock Exchange). It has a market capitalization of £80m ($132m) and is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. SCIB1 is dellivered as a DNA plasmid using Ichor’s TriGrid electroporation device. Clinical trials have shown that SCIB1 produced a compelling melanoma-specific T cell response and highly promising survival trend. The profile suggests that SCIB1 has a place both in combination with the check point inhibitors and as monotherapy for earlier stage disease. Scancell has several other ImmunoBody vaccines in the pipeline targeting other well know cancer targets. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells and that destroy tumours without toxicity. The Moditope® platform deploys certain tumour-associated peptide epitopes as immunotherapeutic agents to overcome self-tolerance and eradicate tumour cells, with no requirement for blockade inhibitors The Moditope® platform has been exemplified by the lead product Modi-1 which exhibits potent anti-tumour efficacy in 'in vivo' therapeutic models. Efficacy has been observed even against aggressive, established tumours, improving survival rates.
Company website:
(0)
(0)